ES2657497T3 - Terapia de combinación de cáncer con anticuerpos antiendoglina y agentes anti-VEGF - Google Patents

Terapia de combinación de cáncer con anticuerpos antiendoglina y agentes anti-VEGF Download PDF

Info

Publication number
ES2657497T3
ES2657497T3 ES10810448.0T ES10810448T ES2657497T3 ES 2657497 T3 ES2657497 T3 ES 2657497T3 ES 10810448 T ES10810448 T ES 10810448T ES 2657497 T3 ES2657497 T3 ES 2657497T3
Authority
ES
Spain
Prior art keywords
cancer
ident
sec
exposed
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10810448.0T
Other languages
English (en)
Inventor
Charles P. Theuer
Ben K. Seon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Health Research Inc
Tracon Pharmaceuticals Inc
Original Assignee
Health Research Inc
Tracon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research Inc, Tracon Pharmaceuticals Inc filed Critical Health Research Inc
Application granted granted Critical
Publication of ES2657497T3 publication Critical patent/ES2657497T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)

Abstract

Un método para inhibir el brote de nuevos vasos inducido por VEGF mediante el contacto de células in vitro con una composición que comprende un anticuerpo antiendoglina quimérico y una composición que comprende un anticuerpo anti-VEGF antagonista; dicho anticuerpo antiendoglina quimérico comprende una región variable de cadena ligera (VL) que tiene una secuencia de aminoácidos que se expone como la sec. con núm. de ident.: 1; una región constante de cadena ligera (CL) que tiene una secuencia de aminoácidos que se expone como la sec. con núm. de ident.: 2; una región variable de cadena pesada (VH) que tiene una secuencia de aminoácidos que se expone como la sec. con núm. de ident.: 3; y una región constante (Fc) que tiene una secuencia de aminoácidos que se expone como la sec. con núm. de ident.: 4.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31
imagen32
imagen33
imagen34
imagen35
imagen36
imagen37
imagen38
imagen39
imagen40
imagen41
imagen42
imagen43
imagen44
imagen45
imagen46
imagen47
imagen48
imagen49
imagen50
imagen51
imagen52
imagen53
imagen54
Tipo de tumor
Régimen de dosis
imagen55
3 semanas por 6 ciclos.
Cáncer de pulmón
Administración de 15 mg/kg por vía intravenosa en el día 1 cada 1 o 3 semanas por 3 o 6 ciclos.
Cáncer cerebral (gliosarcomas y gliomas)
Administración de 10 mg/kg semanalmente o una semana sí y otra no por 6 ciclos.
Cuatro (4) ciclos de administración de 10 mg/kg cada 7 o 14 días.
imagen56
Administración de 15 mg/kg cada semana o cada 3 semanas.
Cáncer de ovario
Administración de 15 mg/kg por vía intravenosa en el día 1, seguido de administración de 15 mg/kg por vía intravenosa cada 7 o 21 días por 5 ciclos.
Carcinoma neuroendocrino
Administración de 15 mg/kg por vía intravenosa durante 90 minutos cada 7 o 21 días.
Cáncer cervical
Administración de 10 mg/kg por vía intravenosa en los días 1, 7 y 15
Cáncer de mama
Administración de 10 mg/kg por vía intravenosa cada 1 o 2 semanas por 2 o 4 ciclos.
Cáncer de próstata
Administración intravenosa cada semana o cada 3 semanas para un total de 17 ciclos por un total de 1 año.
Cáncer de hígado
Administración de 10 mg/kg por vía intravenosa cada 7 o 14 días, con repetición del ciclo cada 28 días.
Cáncer pancreático
Administración de 10 a 15 mg/kg por vía intravenosa durante 90 minutos cada 1 o 2 semanas.
Cáncer metastásico de cabeza y cuello
Administración de 15 mg/kg por vía intravenosa cada 1 o cada 3 semanas.
Ejemplo 10
Expresión de endoglina (CD105) en tipos de tumores sólidos
5 La expresión de endoglina en tumores sólidos se evaluó mediante el uso de inmunohistoquímica. Muestras de carcinoma humano congeladas y fijadas con acetona se dejaron reaccionar con una dilución de 10.000 veces de ascitis con el anticuerpo antiendoglina SN6j o ascitis con una IgG de control del mismo isotipo y se tiñeron con estuches de tinción DAKO. La tinción de contraste se realizó con hematoxilina. El SN6j se unió a los vasos sanguíneos dentro del
10 tumor, mientras que la IgG de control del mismo isotipo no mostró tinción alguna. Todos los tipos de tumor probados demostraron expresión de endoglina dentro dela vasculatura del tumor.
Tumor
Número de especímenes Reactividad (0,+,++,+++)
Vejiga
2 +++
Hueso
1 +++
Mama
21 +++
Colon
4 +++
Esófago
1 +++
Hígado
1 +++
Pulmón
3 +++
Linfoma
7 +++
Ovario
2 +++/++
Páncreas
1 +++
Pene
1 +++
Recto
2 +++
56
imagen57
imagen58
imagen59
imagen60
imagen61
imagen62
imagen63
imagen64
imagen65

Claims (1)

  1. imagen1
    imagen2
ES10810448.0T 2009-08-17 2010-08-16 Terapia de combinación de cáncer con anticuerpos antiendoglina y agentes anti-VEGF Active ES2657497T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23457409P 2009-08-17 2009-08-17
US234574P 2009-08-17
PCT/US2010/045651 WO2011022339A1 (en) 2009-08-17 2010-08-16 Combination therapy of cancer with anti-endoglin antibodies and anti-vegf agents

Publications (1)

Publication Number Publication Date
ES2657497T3 true ES2657497T3 (es) 2018-03-05

Family

ID=43607295

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10810448.0T Active ES2657497T3 (es) 2009-08-17 2010-08-16 Terapia de combinación de cáncer con anticuerpos antiendoglina y agentes anti-VEGF

Country Status (12)

Country Link
US (3) US20120244147A1 (es)
EP (3) EP2722055A1 (es)
JP (3) JP5746174B2 (es)
KR (2) KR20150089096A (es)
CN (1) CN102711809B (es)
AU (1) AU2010284433B2 (es)
CA (1) CA2772240C (es)
EA (1) EA025367B1 (es)
ES (1) ES2657497T3 (es)
HK (1) HK1245119A1 (es)
IL (1) IL218011A (es)
WO (1) WO2011022339A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102325550B (zh) * 2008-12-16 2016-10-26 Qlt公司 光动力学疗法和抗vegf剂在治疗有害的脉络膜新血管系统中的联合应用
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
EP2804620A4 (en) * 2012-01-18 2016-04-13 Neumedicines Inc IL-12 FOR RADIATION PROTECTION AND RADIATION-RELATED TOXICITY WEAKENING
UA115789C2 (uk) * 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
JP6211380B2 (ja) * 2012-10-17 2017-10-11 丸善製薬株式会社 Ｔｉｅ２活性化剤、血管新生抑制剤、血管の成熟化剤、血管の正常化剤、及び血管の安定化剤
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
JP2017537084A (ja) 2014-11-12 2017-12-14 トラコン ファーマシューティカルズ、インコーポレイテッド 抗エンドグリン抗体及びその用途
IL290457B1 (en) 2015-12-30 2024-10-01 Kodiak Sciences Inc Antibodies and their conjugates
WO2018067819A1 (en) * 2016-10-06 2018-04-12 Tracon Pharmaceuticals, Inc. Compositions and methods for treatment of cancers
EP3731865A1 (en) 2017-12-29 2020-11-04 F. Hoffmann-La Roche AG Method for improving vegf-receptor blocking selectivity of an anti-vegf antibody
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
TW202019476A (zh) * 2018-07-26 2020-06-01 日商參天製藥股份有限公司 伴隨視網膜纖維化之眼部疾病之藥劑
WO2020127864A1 (en) * 2018-12-21 2020-06-25 F. Hoffmann-La Roche Ag Method for improving inhibition of vegf-binding to vegf-r1 of an anti-vegf antibody
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN112426526B (zh) * 2021-01-25 2021-04-06 北京达熙生物科技有限公司 一种nk细胞的制备方法及其在治疗癌症中的应用
CN115991773B (zh) * 2022-08-15 2023-11-17 营龄(武汉)生物科技有限公司 一种含有人血白蛋白的药物组合物
WO2024163905A1 (en) * 2023-02-03 2024-08-08 Genzyme Corporation Hsc-specific antibody conjugated lipid nanoparticles and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US928641A (en) * 1908-10-09 1909-07-20 Levi E Edmunds Clasp for pilings.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5308626A (en) 1985-06-28 1994-05-03 Toni N. Mariani Lymphokine activated effector cells for antibody-dependent cellular cytotoxicity (ADCC) treatment of cancer and other diseases
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
ES2169864T3 (es) 1996-05-31 2002-07-16 Health Research Inc Anticuerpos monoclonales anti-endoglina y su uso en terapia anti-angiogenesis.
US6190660B1 (en) 1996-05-31 2001-02-20 Health Research, Inc. Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ATE336514T1 (de) 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
ATE472609T1 (de) 2001-04-26 2010-07-15 Amgen Mountain View Inc Kombinatorische bibliotheken von monomerdomänen
US7371849B2 (en) 2001-09-13 2008-05-13 Institute For Antibodies Co., Ltd. Methods of constructing camel antibody libraries
US20030124132A1 (en) * 2001-09-27 2003-07-03 Board Of Regents, The University Of Texas System Combined compositions for tumor vasculature coaguligand treatment
MXPA04009681A (es) * 2002-04-05 2005-01-11 Amgen Inc Anticuerpos humanos neutralizantes anti-ligando de osteoprotegerina como inhibidores selectivos de la ruta del ligando de osteoprotegerina.
US7217798B2 (en) 2003-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of Fc-fusion protein serum half-lives by mutagenesis
US7097836B1 (en) 2002-10-23 2006-08-29 Health Research, Inc. Method for increasing the efficacy of anti-tumor agents by anti-endoglin antibody
DE10303664A1 (de) * 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
MXPA05012723A (es) * 2003-05-30 2006-02-08 Genentech Inc Tratamiento con anticuerpos anti-vgf.
EP1675878A2 (en) 2003-10-24 2006-07-05 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
US8003108B2 (en) * 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US8053569B2 (en) 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
US8007797B2 (en) * 2006-09-28 2011-08-30 Merck Serono S.A. Junctional adhesion molecule-C (JAM-C) binding compounds and methods of their use
CA2689913C (en) * 2007-06-06 2014-10-07 Research Development Foundation Rtef-1 variants and the use thereof for inhibition of angiogenesis
WO2009033581A1 (en) * 2007-09-14 2009-03-19 Bayer Schering Pharma Aktiengesellschaft Substituted tricyclic compounds and methods of use thereof
TWI468417B (zh) * 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
WO2009091810A1 (en) * 2008-01-14 2009-07-23 Genentech, Inc. Methods for inhibiting angiogenesis using egfl8 antagonists
US20100082438A1 (en) * 2008-10-01 2010-04-01 Ronnie Jack Garmon Methods and systems for customer performance scoring

Also Published As

Publication number Publication date
EA025367B1 (ru) 2016-12-30
CA2772240A1 (en) 2011-02-24
EA201290104A1 (ru) 2013-01-30
CA2772240C (en) 2017-12-05
WO2011022339A1 (en) 2011-02-24
IL218011A0 (en) 2012-04-30
CN102711809B (zh) 2015-09-30
US20180371072A1 (en) 2018-12-27
JP2014088401A (ja) 2014-05-15
EP2722055A1 (en) 2014-04-23
EP2467156A1 (en) 2012-06-27
AU2010284433B2 (en) 2013-12-05
CN102711809A (zh) 2012-10-03
JP2016065059A (ja) 2016-04-28
HK1245119A1 (zh) 2018-08-24
JP2013502422A (ja) 2013-01-24
EP2467156A4 (en) 2013-04-03
KR20120108964A (ko) 2012-10-05
US20200087389A1 (en) 2020-03-19
JP6000427B2 (ja) 2016-09-28
US20120244147A1 (en) 2012-09-27
KR101553740B1 (ko) 2015-09-17
JP5829260B2 (ja) 2015-12-09
IL218011A (en) 2017-09-28
KR20150089096A (ko) 2015-08-04
AU2010284433A1 (en) 2012-03-15
JP5746174B2 (ja) 2015-07-08
EP3281637A1 (en) 2018-02-14
EP2467156B1 (en) 2017-11-01

Similar Documents

Publication Publication Date Title
ES2657497T3 (es) Terapia de combinación de cáncer con anticuerpos antiendoglina y agentes anti-VEGF
US20220105184A1 (en) Compositions, combinations and related methods for photoimmunotherapy
ES2654623T3 (es) Inhibidores bivalentes de proteínas IAP y métodos terapéuticos que los usan
HRP20201090T1 (hr) Protutijela anti-icos
BR112020008888A2 (pt) terapias de combinação
HRP20200881T1 (hr) Antitijela koja vežu beta-klotho domenu 2 i postupci njihove uporabe
ES2865068T3 (es) Anticuerpos terapéuticos contra la proteína ROR-1 y métodos para usarlos
ES2367675T3 (es) Anticuerpo anti-epcam y usos del mismo.
DOP2019000280A (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso
RU2016146993A (ru) Комбинация антитела к CCR4 и агониста 4-1BB для лечения рака
JP2024037894A5 (es)
IL292193B1 (en) Anti-B7-H1 antibodies for the treatment of tumors
AR069062A1 (es) Anticuerpo anti-hepcidina
CN105999263A (zh) 用于治疗或预防人表皮生长因子受体-3(her-3)相关疾病的材料和方法
RU2017117596A (ru) Связывающие молекулы, специфичные в отношении CD73, и пути их применения
RU2017117664A (ru) Комбинация
PE20141908A1 (es) Anticuerpos cd47 y metodos de uso los mismos
RU2015104001A (ru) Комбинированная терапия для лечения глиобластомы
JP2016530323A5 (es)
EA029214B1 (ru) Композиции антител и их применения
ES2759329T3 (es) Anticuerpos contra la anfirregulina, composiciones que los comprenden y usos de los mismos
RU2014125520A (ru) Биомаркеры плазмы крови в случае комбинированной терапии бевацизумабом для лечения рака груди
RU2016143552A (ru) Гуманизированные антитела к антигену Томсена-Фриденрайха
Polani et al. Stroma-targeting strategies in pancreatic cancer: Past lessons, challenges and prospects
EA202192587A1 (ru) Антитела к cd73, антитела к pd-l1 и химиотерапия для лечения опухолей